DrugDashboards

Ketamine Hydrochloride

Ketamine Hydrochloride · KETAMINE HYDROCHLORIDE 100 mg/mL · Injection, Solution · Intramuscular; Intravenous · Sagent Pharmaceuticals

NDC 25021-0684-05 · 10 VIAL in 1 CARTON / 5 mL in 1 VIAL · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $1.54 per mL over the past year. Put together: worth watching — several of the pressures that precede supply trouble are present at once. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$1.00$2.00Nov 2025Sep 2026$1.54
10 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$151.00
Reported to Texas DSHS · 2026 annual filing · Sagent Pharmaceuticals

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$11
11 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 2 active manufacturers+20
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for ketamine hydrochloride (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA216809
TE code
AP
Approval date
Jan 24, 2023
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Ketamine Hydrochloride (Injection, Solution)

LabelerStrengthFirst seenLast seen
Gland Pharma LimitedKETAMINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Gland Pharma LimitedKETAMINE HYDROCHLORIDE 100 mg/mLJul 15, 2026Sep 2, 2026
Gland Pharma LimitedKETAMINE HYDROCHLORIDE 50 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsKETAMINE HYDROCHLORIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsKETAMINE HYDROCHLORIDE 100 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsKETAMINE HYDROCHLORIDE 50 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ketamine Hydrochloride — NDC 25021-0684-05," retrieved September 3, 2026, https://drugdashboards.com/drug/25021068405.

Free to cite with attribution — see how the data is put together.